Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

  1. An update on the drug safety of treating erectile dysfunction

    Research output: Contribution to journalReviewResearchpeer-review

  2. Cardiovascular safety and benefits of GLP-1 receptor agonists

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hormonal contraception, thrombosis and age

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Trials of bevacizumab in breast cancer - a safety review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Type 2 diabetes (T2D) is a progressive disease with increasing prevalence in most countries. The majority of patients with T2D have inadequate glycaemic control, which increases the risk of diabetic complications later in life. New therapies with improved safety profiles are required to tackle the progressive nature of T2D. Areas covered: The efficacy and safety profile of IDegLira - a once-daily, fixed-ratio combination of insulin degludec and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for the treatment of T2D - has been extensively evaluated. IDegLira's phase 3 clinical trial programme builds upon the clinical programmes of its mono-components, and their cardiovascular outcomes trials. The results are described here, focusing on different patient populations and compared with alternative insulin regimens. Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects. Accordingly, co-formulations such as IDegLira are likely to be increasingly preferred over stepwise addition and titration of the individual agents in the management of T2D.

Original languageEnglish
JournalExpert Opinion on Drug Safety
Volume16
Issue number3
Pages (from-to)387-396
Number of pages10
ISSN1474-0338
DOIs
Publication statusPublished - Mar 2017

    Research areas

  • Blood Glucose, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Long-Acting, Liraglutide, Weight Gain, Journal Article, Review

ID: 52661523